Concert Pharmaceuticals, Inc.
Deuterated GFT-505
Last updated:
Abstract:
This invention relates to novel deuterated forms of GFT-505, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are characterized by reduced PPAR-alpha and/or PPAR-delta activity.
Status:
Grant
Type:
Utility
Filling date:
16 Feb 2017
Issue date:
15 Oct 2019